Pharma : Chemo Therapy
Chemo Therapy for Soft Tissue Sarcoma & Ovarian Cancer.
Yondelis 0.25 mg powder for concentrate for solution for infusion.
Yondelis is indicated for the treatment of adult patients with advanced soft tissue sarcoma, after failure of anthracyclines and ifosfamide, or who are unsuited to receive these agents. Efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.
Yondelis contains the active substance Trabectedin. It is a chemotherapeutic agent that prevents the proliferation of cancer cells. Yondelis in combination with pegylated liposomal doxorubicin (PLD) is indicated for the treatment of patients with relapsed platinum-sensitive ovarian cancer.
Yondelis is presented as a powder for solution for infusion. Each vial of powder contains 0.25 mg of trabectedin.